Santen Pharmaceutical Co. Ltd
Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker for the treatment of glaucoma and ocular hypertensio… Read more
Santen Pharmaceutical Co. Ltd (SNPHF) - Total Liabilities
Latest total liabilities as of March 2025: $124.10 Billion USD
Based on the latest financial reports, Santen Pharmaceutical Co. Ltd (SNPHF) has total liabilities worth $124.10 Billion USD as of March 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Santen Pharmaceutical Co. Ltd - Total Liabilities Trend (2005–2025)
This chart illustrates how Santen Pharmaceutical Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Santen Pharmaceutical Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Santen Pharmaceutical Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Minor International Public Company Limited
PINK:MINOF
|
USA | $291.15 Billion |
|
Shenzhen Sunlord Electronics Co Ltd
SHE:002138
|
China | CN¥6.07 Billion |
|
PrairieSky Royalty Ltd
PINK:PREKF
|
USA | $604.50 Million |
|
Quálitas Controladora S.A.B. de C.V
OTCGREY:QUCOF
|
USA | $96.22 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥5.52 Billion |
|
Avanza Bank Holding AB (publ)
ST:AZA
|
Sweden | Skr409.12 Billion |
|
Vietnam Rubber Group Ltd
VN:GVR
|
Vietnam | ₫23.91 Trillion |
Liability Composition Analysis (2005–2025)
This chart breaks down Santen Pharmaceutical Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Santen Pharmaceutical Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Santen Pharmaceutical Co. Ltd (2005–2025)
The table below shows the annual total liabilities of Santen Pharmaceutical Co. Ltd from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $124.10 Billion | -4.78% |
| 2024-03-31 | $130.33 Billion | +1.91% |
| 2023-03-31 | $127.88 Billion | +3.86% |
| 2022-03-31 | $123.13 Billion | +29.20% |
| 2021-03-31 | $95.30 Billion | -10.27% |
| 2020-03-31 | $106.21 Billion | +7.70% |
| 2019-03-31 | $98.61 Billion | -2.27% |
| 2018-03-31 | $100.91 Billion | +46.47% |
| 2017-03-31 | $68.89 Billion | -27.78% |
| 2016-03-31 | $95.39 Billion | +3.21% |
| 2015-03-31 | $92.42 Billion | +85.23% |
| 2014-03-31 | $49.90 Billion | +44.59% |
| 2013-03-31 | $34.51 Billion | +1.67% |
| 2012-03-31 | $33.94 Billion | +19.52% |
| 2011-03-31 | $28.40 Billion | -3.00% |
| 2010-03-31 | $29.27 Billion | +14.16% |
| 2009-03-31 | $25.64 Billion | -12.86% |
| 2008-03-31 | $29.43 Billion | -3.36% |
| 2007-03-31 | $30.45 Billion | -4.30% |
| 2006-03-31 | $31.82 Billion | +0.26% |
| 2005-03-31 | $31.74 Billion | -- |